Compare Hershey Co (HSY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Revvity Inc — how do they compare? Hershey Co trades at $162.74 (market cap $32.66B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Hershey Co is the larger of the two by market cap, and Hershey Co pays the higher dividend (3.57%). Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Revvity Inc for 12 Days on average.
| HSY | RVTY | |
|---|---|---|
Market Cap | $32.66B | $16.98B |
Volume | 1,578,237 | 1,456,900 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $157.36 |
52-Week Low | $157.61 | $82.26 |
Typical Hold Time | 135 Days | 12 Days |
Enterprise Value | $37.79B | $19.30B |
Dividend Yield | 3.57% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $162.54, up 1.37% with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 12.24% net margin and 32.81% ROE, though 2025 net income declined to $883M. Analyst consensus targets $204.62 with 65.72% hold ratings, while recent news highlights dividend resumption and international leadership changes.
HSY offers value near 52-week lows with 25% upside to consensus target, supported by consistent earnings outperformance and brand strength. Key risks include cocoa cost pressures, margin compression from 2025 results, and technical bearish momentum. The dividend yield of 3.57% provides income support during market volatility.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
